歌礼制药-B：股价涨 3.32% 减肥药催化

和讯网2025-05-08

【歌礼制药-B午前股价上涨 3.32%，现报 6.54 港元，成交额 773.63 万港元】歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。ASC47 是歌礼自主研发的、脂肪靶向、超长效皮下注射选择性小分子激动剂，美国食品药品监督管理局已批准其与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外，有传闻...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533929301?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-08 12:42","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533929301","market":"hk","top_or_hot":-1,"title":"歌礼制药-B：股价涨 3.32% 减肥药催化","media":"和讯网","content":"<div>\n<p>【歌礼制药-B午前股价上涨 3.32%，现报 6.54 港元，成交额 773.63 万港元】歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。ASC47 是歌礼自主研发的、脂肪靶向、超长效皮下注射选择性小分子激动剂，美国食品药品监督管理局已批准其与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外，有传闻...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B：股价涨 3.32% 减肥药催化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B：股价涨 3.32% 减肥药催化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-08 12:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【歌礼制药-B午前股价上涨 3.32%，现报 6.54 港元，成交额 773.63 万港元】歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。ASC47 是歌礼自主研发的、脂肪靶向、超长效皮下注射选择性小分子激动剂，美国食品药品监督管理局已批准其与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外，有传闻...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b","article_id":"2533929301","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505081441239752da30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533929301","pubTimestamp":1746679365,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。此外，有传闻称“世卫组织计划首次将减肥药纳入基本药物目录以治疗成人肥胖症”。5 月 7 日，世卫组织正式回应，治疗成年肥胖患者的指南正按程序全面制定，预计 2025 年 8 月或 9 月出台最终方案。中信证券此前指，预计后续相关事件将对减肥药板块形成反复催化，有望形成跨年度的主题行情。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1191":"制药","01672":"歌礼制药-B","BK1161":"生物科技","01477":"欧康维视生物-B","BK1515":"抗疫概念"},"translate_title":"Ascletis Pharmaceuticals-B: Stock price rose 3.32% catalyzed by weight loss pills","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"【歌礼制药-B午前股价上涨 3.32%，现报 6.54 港元，成交额 773.63 万港元】歌礼制药近日称将在西班牙马拉加举行的第 32 届欧洲肥胖症大会上以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物 ASC47 的早期研究。ASC47 是歌礼自主研发的、脂肪靶向、超长效皮下注射选择性小分子激动剂，美国食品药品监督管理局已批准其与司美格鲁肽联用治疗肥胖症的新药临床试验申请。此外，有传闻称“世卫组织计划首次将减肥药纳入基本药物目录以治疗成人肥胖症”。5 月 7 日，世卫组织正式回应，治疗成年肥胖患者的指南正按程序全面制定，预计 2025 年 8 月或 9 月出台最终方案。中信证券此前指，预计后续相关事件将对减肥药板块形成反复催化，有望形成跨年度的主题行情。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533929301","isCrawlerRequest":true}